Work

New Opportunities and Cautionary Insights about Decentralizing and Deglobalizing Clinical Trials During the Great Lockdown

Year: 2020

Type: article

Abstract: The 2020s began with a rare coronavirus (COVID-19) disaster, which led to a pandemic-induced recession and Great Lockdown. In response, there has been a worldwide mobilization of resources to detect, treat, and cure the virus. Some policymakers are advocating for the repatriation of globally distributed healthcare know-how. Without a cure for COVID-19, the ambiguity concerning how coronavirus-related policies will impact international business remains unclear. Through a multi-method approach, our study sheds light on two key healthcare industry trends: decentralization and deglobalization of clinical trials. We offer actionable strategies to not only mitigate these challenges, but also to take advantage of their new opportunities.

Source: AIB Insights

DOI: 10.46697/001c.17692

Authors: Denise Dunlap, Roberto S. Santos, David D. McManus, Bryan O. Buchholz, Nathaniel S. Hafer, MaryAnn Picard

Institutions: University of Massachusetts Lowell, University of Massachusetts Chan Medical School

Language: English

Topic: Pharmaceutical Economics and Policy

Subfield: Economics and Econometrics

Field: Economics, Econometrics and Finance

Domain: Social Sciences

SDG: Good health and well-being

Open Access status: diamond

Funders: National Institutes of Health, National Heart, Lung, and Blood Institute, National Center for Advancing Translational Sciences